After approval by the FDA, AVT03 is expected to be supplied in a single-dose prefilled syringe containing 60 mg in a 1 ml solution, as well as a 120 mg/1.7 ml solution in a single-dose vial.

Reykjavik, Iceland Friday, March 21, 2025, 12:00 Hrs [IST] ...

The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous ...

The label expansion couls help J&J establish Tremfya as a successor to Stelara, which is now facing a growing biosimilar ...

Over the last 7 days, the United States market has risen by 2.8% and over the past 12 months, it is up by 7.6%, with earnings expected to grow by 14% per annum over the next few years. In this ...

The United States market has experienced a positive trend, rising 2.8% in the last week and climbing 7.6% over the past year, with all sectors showing gains and earnings projected to grow by 14% ...